Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 2/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777480 | 0.82 | HTR6 (0.60) | SMARCA2SMARCA4PBRM1HTR6SCN9A | |
| SCHEMBL24330045 | 0.80 | GPR119 (0.45) | SCN9AMMP13GPR119 | |
| SCHEMBL1570643 | 0.80 | HTR6 (0.58) | HTR6SCN9A | |
| SCHEMBL20111957 | 0.78 | SCN9A (0.44) | SCN9AMMP13JAK2JAK3GPR119 | |
| SCHEMBL20009090 | 0.76 | SMARCA2 (0.71) | SMARCA2SMARCA4PBRM1GPR119MAPT | |
| SCHEMBL30606905 | 0.76 | SMARCA2 (0.71) | SMARCA2SMARCA4PBRM1GPR119MAPT | |
| SCHEMBL16610232 | 0.75 | SCN9A (0.44) | HTR6SCN9AMMP13GPR119 | |
| SCHEMBL22777626 | 0.75 | SMARCA2 (0.54) | SMARCA2SMARCA4PBRM1JAK2JAK3 | |
| SCHEMBL31270546 | 0.74 | HTR6 (0.48) | HTR6SCN9AGPR119TGFBR1 | |
| SCHEMBL25032332 | 0.74 | HTR6 (0.48) | HTR6SCN9AGPR119TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2020251974-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCA1, SMARCE1, PBRM1 | SMARCA2 7/4885SMARCA4 8/4885PBRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.